1. 25 years International Bladder Cancer Network (IBCN): the past, the presence, and the future;Dyrskjøt;Urol Oncol,2022
2. Reike MJ, Ingersoll M, Müller D, Zuiverloon TCM, Strandgaard T, Kamat AM, Williams SB, Seiler R, Todenhöfer T, Dyrskjøt L, Nawroth R, Goebell P, Schmitz-Dräger B, Sfakianos J, Meeks J, Horowitz A, Black PC. Biology of BCG-response in Non-Muscle-Invasive Bladder Cancer –2021 IBCN Updates Part III. Urol Oncol 2022 Oct 17:S1078-1439(22)00340-4.
3. Circulating tumor DNA in bladder cancer –2021 IBCN Updates Part II;Christensen;Urol Oncol,2022
4. Hensley PJ, Seiler R, Herr H, Mouw KW, Iyver G, Dyrskjøt L, et al. Bladder preservation after neoadjuvant therapy –2021 IBCN Updates Part I. Urol Oncol
5. Clinical value of 18FDG PET/MRI in muscle-invasive, locally advanced, and metastatic bladder cancer;Civelek;Urol Oncol,2021